Skip to content
TriangleGet started
← Back to this collection

PUBLICATIONS · 30897038

AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
J Clin Oncol
Publication date
2019 May 10
First author
Leonard JP

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    J Clin Oncol. 2019 May 10;37(14):1151-1153. doi: 10.1200/JCO.19.00419.
    note
    Source null
    related pmid
    30901301
    relationship
    Comment in

Authors and identifiers

  1. name
    Leonard JP
    type
    Author
  2. name
    Trneny M
    type
    Author
  3. name
    Izutsu K
    type
    Author
  4. name
    Fowler NH
    type
    Author
  5. name
    Hong X
    type
    Author
  6. name
    Zhu J
    type
    Author
  7. name
    Zhang H
    type
    Author
  8. name
    Offner F
    type
    Author
  9. name
    Scheliga A
    type
    Author
  10. name
    Nowakowski GS
    type
    Author
  11. name
    Pinto A
    type
    Author
  12. name
    Re F
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Leonard JP
    type
    Author
  2. name
    Trneny M
    type
    Author
  3. name
    Izutsu K
    type
    Author
  4. name
    Fowler NH
    type
    Author
  5. name
    Hong X
    type
    Author
  6. name
    Zhu J
    type
    Author
  7. name
    Zhang H
    type
    Author
  8. name
    Offner F
    type
    Author
  9. name
    Scheliga A
    type
    Author
  10. name
    Nowakowski GS
    type
    Author
  11. name
    Pinto A
    type
    Author
  12. name
    Re F
    type
    Author
bibliography ids
  1. nci-bib-58fd391205d2b383dcdb42a5
book metadata
content sha256
6f0292a8fccf830f94d1b8495dcb6569fa789b028a080a9416a17d24974bfa4c
document type
citation
dois
  1. 10.1200/JCO.19.00010
electronic publication date
display
2019 Mar 21
precision
day
year
2019
evidence scope
bibliographic_metadata_only
id
pubmed:30897038
immutable id
pubmed:30897038@6f0292a8fccf830f94d1b8495dcb6569fa789b028a080a9416a17d24974bfa4c
journal
abbreviation
J Clin Oncol
issn electronic
1527-7755
issn print
0732-183X
issue
14
name
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
nlm unique id
8309333
pages
1188-1199
volume
37
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    J Clin Oncol. 2019 May 10;37(14):1151-1153. doi: 10.1200/JCO.19.00419.
    note
    Source null
    related pmid
    30901301
    relationship
    Comment in
outcomes validated
false
pmid
30897038
provenance
batch id
e808962322f3afebc564
provider
NCBI PubMed ESummary
record sha256
73b944e29e0006d3cab62571a475b0d52e6c033cc9352f84c3c42407c795ea17
response sha256
3d610336ca8dae92b82cdb6b3ee6cab382eb509e0349b0c68c261b042b036561
retrieved at
2026-09-09T23:47:41.002093+00:00
publication date
display
2019 May 10
precision
day
year
2019
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/30897038/
title
AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma.

Preserved source evidence · Independent clinical review pending · Not medical advice